'CARMEN': is less, more? Lessons from trials in human immunodeficiency virus-Burkitt lymphoma (HIV-BL)

Affiliations

¹ Department of Haematology, University College London Hospital, London, UK.
² Department of Haematology, St Bartholomew's and The Royal London NHS Trust, London, UK.

Comment

Kate Cwynarski et al. Br J Haematol. 2021 Jan.

. 2021 Jan;192(1):13-14.

doi: 10.1111/bjh.17187. Epub 2020 Oct 22.

¹ Department of Haematology, University College London Hospital, London, UK.
² Department of Haematology, St Bartholomew's and The Royal London NHS Trust, London, UK.

No abstract available

Keywords: HIV-BL; combination antiretroviral therapy; lymphoma.

Comment on

A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, Pecciarini L, Donadoni G, Fumagalli L, Sassone M, Calimeri T, Rossi G, Spina M, Re A. Ferreri AJM, et al. Br J Haematol. 2021 Jan;192(1):119-128. doi: 10.1111/bjh.17188. Epub 2020 Oct 21. Br J Haematol. 2021. PMID: 33085777 Clinical Trial.

1. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181-91.
1. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116:5600-4.
1. Lawn SD, Török ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis. 2011;24:34-42.
1. Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol. 2017;35:3774-80.
1. Phillips EH, Burton C, Kirkwood AA, Barrons S, Lawrie A, Rule S, et al. Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: results of a phase 2 UK NCRI trial. eJHaem. 2020;1:133-41.